20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years,The New England Journal of Medicine

当前位置： X-MOL 学术 › N. Engl. J. Med. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
The New England Journal of Medicine ( IF 96.2 ) Pub Date : 2017-11-08 , DOI: 10.1056/nejmoa1701830
Hongchao Pan ₁ , Richard Gray ₁ , Jeremy Braybrooke ₁ , Christina Davies ₁ , Carolyn Taylor ₁ , Paul McGale ₁ , Richard Peto ₁ , Kathleen I Pritchard ₁ , Jonas Bergh ₁ , Mitch Dowsett ₁ , Daniel F Hayes ₁ ,

Affiliation

After 5 years of adjuvant endocrine therapy, breast-cancer recurrences continued to occur steadily throughout the study period from 5 to 20 years. The risk of distant recurrence was strongly correlated with the original TN status, with risks ranging from 10 to 41%, depending on TN status and tumor grade. (Funded by Cancer Research UK and others.)

中文翻译：